Grifols (GRFS)
(Delayed Data from NSDQ)
$6.48 USD
+0.10 (1.57%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $6.49 +0.01 (0.15%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.48 USD
+0.10 (1.57%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $6.49 +0.01 (0.15%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth C Momentum C VGM
Zacks News
Is Grifols (GRFS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Grifols (GRFS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Sell Stocks for January 13th (Revised)
by Zacks Equity Research
GEVO, GRFS and ABM have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2023.
New Strong Sell Stocks for January 13th
by Zacks Equity Research
GEVO, GRFS and ABM have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2023.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
New Strong Sell Stocks for January 6th
by Zacks Equity Research
CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022
New Strong Sell Stocks for September 22nd
by Zacks Equity Research
MANU, GRFS, IMCC, and INTZ have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2021
Moving Average Crossover Alert: Grifols (GRFS)
by Zacks Equity Research
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
New Strong Sell Stocks for March 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: Grifols
by Zacks Equity Research
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Is Grifols (GRFS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis
by Zacks Equity Research
Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
by Zacks Equity Research
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Should Value Investors Consider Grifols (GRFS) Stock Now?
by Zacks Equity Research
Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
How Grifols (GRFS) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Grifols (GRFS) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for March 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today: